Extended 73-month survival in an elderly patient with BRAF V600E-mutated lung adenocarcinoma: A case report.

IF 0.8 Q4 RESPIRATORY SYSTEM

Respirology Case Reports Pub Date : 2024-10-07 eCollection Date: 2024-10-01 DOI:10.1002/rcr2.70040

Kensuke Namba, Kazutoshi Isobe, Hiroki Wakabayashi, Ryogo Ohashi, Hiromasa Sakurai, Daiki Sakai, Yusuke Irie, Kenta Takashima, Yu Murakami, Kaichi Kaneko, Nobuyuki Hiruta, Yasuo Matsuzawa

{"title":"Extended 73-month survival in an elderly patient with BRAF V600E-mutated lung adenocarcinoma: A case report.","authors":"Kensuke Namba, Kazutoshi Isobe, Hiroki Wakabayashi, Ryogo Ohashi, Hiromasa Sakurai, Daiki Sakai, Yusuke Irie, Kenta Takashima, Yu Murakami, Kaichi Kaneko, Nobuyuki Hiruta, Yasuo Matsuzawa","doi":"10.1002/rcr2.70040","DOIUrl":null,"url":null,"abstract":"<p><p>BRAF is a mediator that activates the mitogen-activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was found to be effective in non-small cell lung cancer (NSCLC) patients with the BRAF mutation. However, this study has limited efficacy and safety data for elderly patients. We present a case of a patient who started treatment at 87 years old and showed a good prognosis, remaining alive 73 months from the start of treatment with no significant adverse events. The patient also maintained a partial response (PR) according to RECIST 1.1 at the last follow-up. This case suggests that the dabrafenib and trametinib combination therapy is safe and effective for elderly NSCLC patients with the BRAF mutation.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

BRAF is a mediator that activates the mitogen-activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was found to be effective in non-small cell lung cancer (NSCLC) patients with the BRAF mutation. However, this study has limited efficacy and safety data for elderly patients. We present a case of a patient who started treatment at 87 years old and showed a good prognosis, remaining alive 73 months from the start of treatment with no significant adverse events. The patient also maintained a partial response (PR) according to RECIST 1.1 at the last follow-up. This case suggests that the dabrafenib and trametinib combination therapy is safe and effective for elderly NSCLC patients with the BRAF mutation.

查看原文本刊更多论文

一名 BRAF V600E 突变肺腺癌老年患者延长 73 个月的生存期：病例报告。

BRAF 是激活有丝分裂原激活蛋白激酶通路的介质。BRAF 基因突变会导致通路激活异常，从而导致细胞增殖。在一项二期研究中，BRAF抑制剂达拉菲尼和MEK抑制剂曲美替尼的联合疗法对BRAF突变的非小细胞肺癌（NSCLC）患者有效。然而，这项研究对老年患者的疗效和安全性数据有限。我们介绍了一例 87 岁开始接受治疗的患者，该患者预后良好，从治疗开始至今已存活 73 个月，且无明显不良反应。根据 RECIST 1.1，该患者在最后一次随访时还保持了部分应答（PR）。该病例表明，达拉非尼和曲美替尼联合疗法对于BRAF突变的老年NSCLC患者是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.